Work

Targeting Syk in Autoimmune Rheumatic Diseases

Year: 2016

Type: review

Abstract: Spleen tyrosine kinase (Syk) is a member of the Src family of non-receptor tyrosine kinases, which associates directly with surface receptors, including B-cell receptor and Fcγ receptor, and is involved in a variety of signal transduction pathways. Rheumatoid arthritis (RA) and systemic lupus erythematosus are autoimmune diseases in which autoantibodies, immune complexes, and autoreactive T cells account for the expression of tissue inflammation and damage. Syk inhibitors efficiently suppress RA in patients albeit in the expression of unwanted side effects, including gastrointestinal effects, hypertension, and neutropenia. Syk inhibitors also inhibit clinical manifestations in lupus-prone mice. Here, we review the evidence that supports the use of Syk inhibitors to treat rheumatic and other autoimmune diseases.

Source: Frontiers in Immunology

DOI: 10.3389/fimmu.2016.00078

Authors: Guo-Min Deng, Vasileios C. Kyttaris, George C. Tsokos

Institutions: State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Beth Israel Deaconess Medical Center, Harvard University

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801